|
1.
|
|
8 p, 1012.2 KB |
Reduced intensity conditioning increases risk of severe cGVHD : identification of risk factors for cGVHD in a multicenter setting
/
Afram, Gabriel (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Simón, Jose Antonio Pérez (Instituto de Biomedicina de Sevilla) ;
Remberger, Mats (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Caballero Velazquez, Teresa (Instituto de Biomedicina de Sevilla) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Piñana, Jose Luis (Hospital Clinico Universitario) ;
Ringden, Olle (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Lopez-Corral, Lucia (Hospital Universitario de Salamanca-IBSAL) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
López-Godino, Oriana (Hospital Universitario de Salamanca-IBSAL) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Caballero, Dolores (Hospital Universitario de Salamanca-IBSAL) ;
Ljungman, Per (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Vazquez, Lourdes (Hospital Clínico Universitario (Salamanca)) ;
Hägglund, Hans (Uppsala University Hospital) ;
Universitat Autònoma de Barcelona
Chronic graft-versus-host disease (cGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Aim is to identify risk factors for the development of cGVHD in a multicenter setting. [...]
2018 -  10.1007/s12032-018-1127-2
Medical Oncology, Vol. 35 Núm. 6 (january 2018) , p. 79
|
|
|
2.
|
|
12 p, 144.7 KB |
Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
/
Puente, J. (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Anido, Urbano (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Climent, M.Á. (Instituto Valenciano de Oncología (IVO)) ;
Gonzalez-Billalabeitia, E. (Universidad Católica San Antonio de Murcia-UCAM) ;
Lainez, N. (Complejo Hospitalario de Navarra) ;
Lambea, Julio (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Mendez-Vidal, M.J. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Montesa, Álvaro (Hospital Regional Universitario de Málaga) ;
Rodriguez, A. (Hospital Universitario de León) ;
Zambrana, C. (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
González-del-Alba, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. [...]
2020 - 10.1177/1758835920920067
Therapeutic Advances in Medical Oncology, Vol. 12 (2020)
|
|
|
3.
|
|
28 p, 884.5 KB |
Cabozantinib for the treatment of solid tumors : a systematic review
/
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari "Aldo Moro) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Viteri, Santiago (UOMI Cancer Center. Clínica Mi Tres Torres) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Martin, Lidia (Ipsen Pharma) ;
Castellano, Daniel (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. [...]
2022 - 10.1177/17588359221107112
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
4.
|
|
12 p, 815.7 KB |
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
/
Ciriaco, Nikaoly (Hospital del Mar (Barcelona, Catalunya)) ;
Zamora, Esther (Hospital Universitari Vall d'Hebron) ;
Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ;
Miranda Gómez, Ignacio (Hospital Universitari Vall d'Hebron) ;
Jiménez Flores, José (Vall d'Hebron Institut d'Oncologia) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Sloane, Hillary ;
Starus, Anna ;
Fredebohm, Johannes ;
Georgieva, Lucy ;
Speight, Graham ;
Jones, Frederick ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Although the standard of care is to perform surgery of primary breast cancer (BC) after neoadjuvant chemotherapy (NAC), for certain patients achieving clinical complete response (cCR) and pathologic complete response (pCR), omission of surgical treatment may be an option. [...]
2022 - 10.1177/17588359221139601
Therapeutic Advances in Medical Oncology, Vol. 14 (november 2022)
|
|
|
5.
|
|
19 p, 511.1 KB |
Uterine sarcomas : clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
/
Pérez-Fidalgo, Jose Alejandro ;
Ortega, Eugenia ;
Ponce, Jordi (Hospital Universitari de Bellvitge) ;
Redondo, Andres ;
Sevilla, Isabel ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Isern Verdum, Josep (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
De Álava, Enrique ;
Galera López, Mar ;
Marquina, Gloria ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Uterine sarcomas are very infrequent and heterogeneous entities. Due to its rarity, pathological diagnosis, surgical management, and systemic treatment are challenging. Treatment decision process in these tumors should be taken in a multidisciplinary tumor board. [...]
2023 - 10.1177/17588359231157645
Therapeutic Advances in Medical Oncology, Vol. 15 (march 2023)
|
|
|
6.
|
|
14 p, 2.0 MB |
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer : patient-reported outcomes from the FLIPPER trial
/
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez, M. Teresa ;
Ramos, Manuel ;
de la Cruz Merino, Luis ;
Santaballa, Ana ;
O'Connor, Miriam ;
Martínez-Jañez, Noelia ;
Moreno, Fernando ;
Fernández, Isaura ;
Virizuela, Juan Antonio ;
Alarcón, Jesús ;
de la Haba Rodríguez, Juan Rafael ;
Sánchez-Rovira, Pedro ;
Albacar, Cinta Rosa ;
Bueno Muiño, Coralia ;
Kelly, Catherine ;
Casas, Maribel ;
Bezares, Susana ;
Rosell, Libertad ;
Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC). [...]
2023 - 10.1177/17588359221148921
Therapeutic Advances in Medical Oncology, Vol. 15 (january 2023)
|
|
|
7.
|
|
37 p, 420.1 KB |
Cabozantinib combination therapy for the treatment of solid tumors : a systematic review
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari 'Aldo Moro') ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas) ;
Martin, Lidia (Ipsen Pharma) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. [...]
2022 - 10.1177/17588359221108691
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
8.
|
|
13 p, 904.0 KB |
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma : data from the AGAMENON-SEOM registry
/
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias. ISPA) ;
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martinez-Torron, Alba (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Custodio, Ana (Hospital Universitario La Paz (Madrid)) ;
Serra, Olbia (Institut Català d'Oncologia) ;
Cacho Lavin, Diego (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sauri, Tamara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
López, Flora (Hospital Universitario 12 de Octubre (Madrid)) ;
Visa, Laura (Hospital Universitario El Mar) ;
Granja, Mónica (Hospital Universitario Clínico San Carlos (Madrid)) ;
Martínez Lago, Nieves (Complejo Hospitalario Universitario de A Coruña) ;
Arrazubi, Virginia (Instituto de Investigación Sanitaria de Navarra) ;
Vidal Tocino, Rosario (Complejo Asistencial Universitario de Salamanca-IBSAL) ;
Hernandez, Raquel (Hospital Universitario de Canarias (La Laguna)) ;
Aguado, Gema (Hospital General Universitario Gregorio Marañón) ;
Cano, Juana María (Hospital General Universitario de Ciudad Real) ;
Martín Carnicero, Alfonso (Hospital San Pedro de Alcántara) ;
Mangas, Montserrat (Hospital de Galdakao (Usansolo, Biscaia)) ;
Pimentel, Paola (Hospital General Universitario Santa Lucía (Cartagena, Múrcia)) ;
Fernández Montes, Ana (Complejo Hospitalario de Orense) ;
Macias Declara, Ismael (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Longo, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ;
Ramchandani, Avinash (Hospital Universitario Insular de Gran Canaria) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Hurtado-Nuño, Alicia (Hospital Universitario Fundación Alcorcón) ;
Azkárate, Aitor (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Hernández Pérez, Carolina (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ;
Serrano, Raquel (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Gallego, Javier (Hospital General Universitario de Elche)
Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. [...]
2021 - 10.1177/17588359211019672
Therapeutic Advances in Medical Oncology, Vol. 13 (2021)
|
|
|
9.
|
|
|
10.
|
|
8 p, 201.2 KB |
Simple, low-cost and timely optical biosensors for the detection of epigenetics biomarkers : the future of cancer diagnosis
/
Huertas, César S. (Institut Català de Nanociència i Nanotecnologia) ;
Lechuga, Laura M (Institut Català de Nanociència i Nanotecnologia)
The cancer burden continues to grow with enormous physical, emotional, and financial pressure on individuals, families, communities, and health systems. Early detection and effective treatment are crucial. [...]
2017
European Medical Journal Oncology, Vol. 5, Núm. 1 (October 2017) , p. 54-61
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
